Boehringer Ingelheim
For Healthcare Professionals
x

Registration Form

Information you provide when registering will be shared with the account owner  and host and can be used and shared by them in accordance with their Terms and Privacy Policy.

gif

November 21, 2024 (Thursday) | 19:00–20:30 pm SGT

Objectives

  • Recapitulate the effectiveness and applicability of empagliflozin in heart failure
  • Contextualize the significance of quality of life and patient improvements seen with empagliflozin
  • Reinforce the importance of early empagliflozin initiation in both HFrEF and HFpEF

Speakers

Prof. Dr. Ricardo Fontes-Carvalho, MD, PhD, FESC, FACC

Director of Cardiology Department at Centro Hospitalar de Gaia/Espinho, Professor of Cardiovascular Science at Faculty of Medicine University of Porto, Portugal.

Prof. Dr. Erin Michos, MD, MHS, FACC, FASE, FASPC

Professor of Medicine, Division of Cardiology and Department of Epidemiology, John Hopkins Bloomberg School of Public Health; Director of Women’s Cardiovascular Health, Associate Director of Preventive Cardiology, Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

Heart Failure 3600

Webinar ID: 916 2937 3547

November 21, 2024 (Thursday) |

Agenda

TimeSessionSpeaker
19:00-19:15OpeningProf. Dr. Ricardo Carvalho
19:15-19:25What can we do for our patients?Prof. Dr. Ricardo Carvalho
19:25-19:45HFrEF: When the heart skips more than just a beatProf. Dr. Ricardo Carvalho
19:45-20:05HFpEF: The heart's silent struggleProf. Dr. Erin Michos
20:05-20:20Live Q&AAll speakers
20:20-20:30Closing and summaryProf. Dr. Ricardo Carvalho